

BLUE SHIELD OF CALIFORNIA FOUNDATION

California Technology Assessment Forum

October 15, 2008

UCSF Mission Bay Conference Center, San Francisco

Summary of Panel Actions

1. Call to Order and Welcome Guests - Ezra Davidson, M.D.
2. Voted to approve the minutes from June 18, 2008 CTAF meeting
3. Welcome from the Blue Shield of California Foundation – Deborah Schwab, R.N., ANP
4. Technology Assessment Criteria review - Jeffrey A. Tice, M.D.
5. Thirteen members of the CTAF panel were in attendance. This provided a quorum. The CTAF panel took the following actions:
 - A. Brachytherapy as Primary Radiation Therapy Following Breast-conserving Surgery for Stage I or II Breast Cancer

The following recommendation was put before the CTAF panel for consideration:

- It is recommended that the use of brachytherapy does not meet CTAF Technology Assessment Criteria 4 or 5 for safety, effectiveness and improvement in health outcomes when used as primary radiation therapy following breast conserving surgery for localized breast cancer.

Following Panel discussion and expert testimony, a motion was made by the CTAF Panel Discussion Leader to approve the recommendation as presented. The motion was seconded.

The CTAF panel voted unanimously in favor of this recommendation.

B. LDL Particle Number

The following recommendation was put before the CTAF panel for consideration:

- It is recommended that measurement of LDL-P does not meet CTAF Technology Assessment Criteria 2 through 5 for efficacy and improvement in health outcomes as an adjunct to LDL-C for individuals with CHD or CHD equivalents or CMS who have already achieved LDL-C goals.

Following Panel discussion and expert testimony, a motion was made by the CTAF Panel Discussion Leader to approve the recommendation as presented. The motion was seconded.

The CTAF panel voted unanimously in favor of this recommendation.

C. Portable Devices Used in Home Testing for Obstructive Sleep Apnea

The following recommendation was put before the CTAF panel for consideration:

- It is recommended that the use of Level III portable home devices to diagnose OSA does not meet CTAF Technology Assessment Criteria 3, 4 or 5 for safety, efficacy and improvement in health outcomes.

Following Panel discussion and expert testimony, a motion was made by the CTAF Panel Discussion Leader for an alternative recommendation:

It is recommended that the use of Level III portable home devices to diagnose OSA does not meet technology assessment criteria 4 or 5 for safety, effectiveness and improvement in health outcomes. The motion was seconded.

The CTAF panel voted six in favor and seven opposed to this recommendation. The motion did not pass.

There was a motion from another panel member then to approve the recommendation as originally written.

- It is recommended that the use of Level III portable home devices to diagnose OSA does not meet technology assessment criteria 3, 4 or 5 for safety, effectiveness and improvement in health outcomes.

The motion was seconded.

The CTAF panel voted six in favor and seven opposed to this recommendation. This motion did not pass.

There was then a motion to table a decision on this topic. The motion was seconded.

The CTAF panel voted twelve in favor of this motion with one abstention.

D. PillCam ESO Capsule for the Evaluation of Esophageal Disease

The following recommendation was put before the CTAF panel for consideration:

- It is recommended that PillCam ESO does not meet CTAF Technology Assessment criteria 3-5 for safety, efficacy and improvement in health outcomes for the evaluation of esophageal disease.

Following Panel discussion a motion was made by the CTAF Panel Discussion leader to approve the recommendation as presented. This motion was seconded.

The CTAF panel voted unanimously in favor of this recommendation.

E. Radiofrequency Micro-remodeling for the Treatment of Female Stress Urinary Incontinence

The following recommendation was put before the CTAF panel for consideration:

- It is recommended that radiofrequency micro-remodeling with the Renessa system meets CTAF criteria 1-5 for safety, effectiveness and improvement in health outcomes for the treatment of moderate to severe female stress urinary incontinence in non-pregnant women who are either not able or not willing to undergo surgery for their SUI treatment.
- It is further recommended that radiofrequency micro-remodeling with the SURx system does not meet CTAF criteria 2-5 for safety, effectiveness and improvement in health outcomes for the treatment of female stress urinary incontinence.

Following Panel discussion a motion was made by the CTAF Panel Discussion leader to approve the recommendation as presented with an understanding that moderate to severe incontinence is defined as a specified score below 60 on the Incontinence Quality of Life (IQOL). This motion was seconded.

The CTAF panel voted eleven in favor and one against the recommendation with one abstention.

The meeting was adjourned at 4:25 P.M. The next meeting of the California Technology Assessment Forum will be held on March 11, 2009 in San Francisco, CA.